Donald S Grant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4468409/publications.pdf

Version: 2024-02-01

430874 395702 2,995 37 18 33 h-index citations g-index papers 38 38 38 4916 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Lassa Fever among Children in Eastern Province, Sierra Leone: A 7-year Retrospective Analysis (2012–2018). American Journal of Tropical Medicine and Hygiene, 2021, 104, 585-592.	1.4	12
2	Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019. Microorganisms, 2021, 9, 586.	3.6	10
3	Post-Ebola Syndrome Presents With Multiple Overlapping Symptom Clusters: Evidence From an Ongoing Cohort Study in Eastern Sierra Leone. Clinical Infectious Diseases, 2021, 73, 1046-1054.	5.8	15
4	Health seeking behavior after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. PLoS Neglected Tropical Diseases, 2021, 15, e0009576.	3.0	8
5	Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. Viruses, 2021, 13, 2325.	3.3	24
6	Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Scientific Reports, 2020, 10, 16030.	3.3	15
7	Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time. Nature Communications, 2020, 11, 4131.	12.8	101
8	High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathogens, 2020, 16, e1008352.	4.7	22
9	Identification of Common CD8 ⁺ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone. Journal of Virology, 2020, 94, .	3.4	15
10	Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. Scientific Reports, 2020, 10, 8724.	3.3	14
11	Ebola-Specific CD8+ and CD4+ T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae. Journal of Infectious Diseases, 2020, 222, 1488-1497.	4.0	13
12	Ophthalmic manifestations and vision impairment in Lassa fever survivors. PLoS ONE, 2020, 15, e0243766.	2.5	17
13	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		O
14	High crossreactivity of human T cell responses between Lassa virus lineages., 2020, 16, e1008352.		0
15	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		O
16	High crossreactivity of human T cell responses between Lassa virus lineages., 2020, 16, e1008352.		0
17	Data set on Lassa fever in post-conflict Sierra Leone. Data in Brief, 2019, 23, 103673.	1.0	12
18	A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. PLoS ONE, 2019, 14, e0214284.	2.5	14

#	Article	IF	CITATIONS
19	Capturing sequence diversity in metagenomes with comprehensive and scalable probe design. Nature Biotechnology, 2019, 37, 160-168.	17.5	96
20	Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Scientific Reports, 2018, 8, 5939.	3.3	39
21	Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. EBioMedicine, 2018, 30, 217-224.	6.1	42
22	Analysis of CD8 ⁺ T cell response during the 2013–2016 Ebola epidemic in West Africa. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7578-E7586.	7.1	55
23	Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature, 2017, 544, 309-315.	27.8	346
24	Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nature Medicine, 2017, 23, 1146-1149.	30.7	95
25	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. Journal of Infectious Diseases, 2016, 214, S110-S121.	4.0	34
26	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nature Communications, 2016, 7, 11544.	12.8	148
27	Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, S203-S209.	4.0	29
28	Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virology, 2015, 10, 559-584.	1.8	18
29	Multiple Circulating Infections Can Mimic the Early Stages of Viral Hemorrhagic Fevers and Possible Human Exposure to Filoviruses in Sierra Leone Prior to the 2014 Outbreak. Viral Immunology, 2015, 28, 19-31.	1.3	33
30	Factors Associated with Mortality in Febrile Patients in a Government Referral Hospital in the Kenema District of Sierra Leone. American Journal of Tropical Medicine and Hygiene, 2015, 92, 172-177.	1.4	11
31	Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell, 2015, 162, 738-750.	28.9	230
32	Lassa Fever in Post-Conflict Sierra Leone. PLoS Neglected Tropical Diseases, 2014, 8, e2748.	3.0	172
33	Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples. Genome Biology, 2014, 15, 519.	8.8	129
34	Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science, 2014, 345, 1369-1372.	12.6	1,083
35	A tribute to Sheik Humarr Khan and all the healthcare workers in West Africa who have sacrificed in the fight against Ebola virus disease: Mae we hush. Antiviral Research, 2014, 111, 33-35.	4.1	19
36	Lassa hemorrhagic fever in a late term pregnancy from northern sierra leone with a positive maternal outcome: case report. Virology Journal, 2011, 8, 404.	3.4	53

#	Article	IF	CITATIONS
37	Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virology Journal, 2011, 8, 478.	3.4	69